Is Quizartinib officially on the market and the channels through which it can be purchased?

Quizartinib (trade name: Vanflyta) is an oral, selective FLT3 inhibitor, mainly used to treat patients with acute myeloid leukemia (AML), especially patients with positive FLT3-ITD mutations. The drug has been approved by the US FDA in July 2023 for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD positive AML patients.

As of July 2025, quizartinib has not yet been officially launched in mainland China. However, in January 2025, Daiichi Sankyo submitted a marketing application for Quizartinib to the China National Food and Drug Administration (NMPA) and it was accepted. The application belongs to the 5.1 category of new drugs, and is indicated for the induction, consolidation and maintenance treatment of FLT3-ITD-positive newly diagnosed AML patients. At present, the drug's launch in China is still in the review stage, and the specific launch time has not yet been determined.

Since Quizartinib is not yet on the market in China, patients who want to use the drug usually need to purchase it through overseas channels. Currently, there are original drugs and generic drugs available on the market. The original drug is produced by Japan's Daiichi Sankyo Company and is more expensive. In addition, Laos Lucius Company also produces generic versions of Quizartinib. The specifications include 17.7 mg × 14 tablets and 26.5 mg × 14 tablets. The price is relatively affordable, about more than 1,000 yuan. When choosing a purchasing channel, patients should ensure that the channel is formal and reliable to ensure drug quality and medication safety.

It should be noted that Quizartinib is a prescription drug and should be used under the guidance of a professional doctor. This drug may causeQTFor cardiac adverse reactions such as interval prolongation and arrhythmia, an electrocardiogram should be performed before use and cardiac function should be closely monitored during treatment. In addition, quizartinib may interact with other drugs, so you should inform your doctor about all drugs you are taking. During the period of using Quizartinib, patients should undergo regular follow-up visits and monitor blood routine, liver and kidney function and other indicators to ensure that the treatment is safe and effective.

Reference materials:https://www.drugs.com/